Asset Management, Venture Capital, Fund of Funds
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
HT Capital, an establishment under Hongtao (HT) Asset Management has been actively investing since 1999. The management team, based between Beijing and Hong Kong covers a full-spectrum of investment activities and strategic portfolio managements in varies sectors including Healthcare, IT and the TMT industry.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
9/2020 | LeJian | Series A | - |
10/2018 | XtalPi | Series B | 46M |
11/2017 | Exicure | Private Placement | 11.2M |
1/2022 | Kula Bio | Series A | 0 |
8/2021 | JOINN Biologics | Series B | 150M |
6/2021 | Inmagene Biopharmaceuticals | Series C | 0 |
12/2015 | AliveGen USA | Series A | - |
7/2018 | Cue | Series B | 0 |
3/2017 | Steminent Biotherapeutics | Series B | - |
7/2019 | TriArm Therapeutics | Series A | 0 |
9/2018 | OncoResponse | Series B | 40M |
8/2016 | Ornim Medical | Series C | 20M |
4/2020 | Kringle Pharma | Venture Round | 0 |
9/2020 | LandSpace | Series C | 0 |
9/2021 | Alebund Pharmaceuticals | Series B | 0 |
5/2019 | Kyulux | Series B | 0 |
5/2018 | 3NT Medical | Series C | 15M |
2/2018 | YouWorld | Seed Round | - |
1/2022 | Kula Bio | Series A | 0 |
9/2021 | Alebund Pharmaceuticals | Series B | 0 |
8/2021 | JOINN Biologics | Series B | 0 |
6/2021 | Inmagene Biopharmaceuticals | Series C | 0 |
9/2020 | LeJian | Series A | - |
9/2020 | LandSpace | Series C | 0 |
4/2020 | Kringle Pharma | Venture Round | 0 |
7/2019 | TriArm Therapeutics | Series A | 0 |
5/2019 | Kyulux | Series B | 0 |
10/2018 | XtalPi | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|